According to the company, the miRNA has been shown to be dysregulated in mouse models of cardiac disease and fibrosis, and "antagonizing miR-21 with therapeutic oligonucleotides … inhibits fibrosis and attenuates cardiac function in such models."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.